Subscribe to our Newsletters !!


    Remdesivir eases back COVID-19 movement in macaques: Study

    Washington, Jun 10 (PTI) Early treatment with the antiviral medication remdesivir has been found to diminish viral load and forestall lung sickness in macaques contaminated with SARS-CoV-2 that causes COVID-19, as indicated by an examination. The discoveries, distributed in the diary Nature on Tuesday, bolster the early utilization of remdesivir treatment in patients with COVID-19

    India’s Zydus Cadila to make Gilead’s potential COVID-19 medication remdesivir

    Indian drugmaker Zydus Cadila said on Friday it marked a non-selective permitting agreement with Gilead Sciences Inc to make and market antiviral medication remdesivir, the main treatment to show improvement in COVID-19 preliminaries. Zydus, recorded as Cadila Healthcare, joins other Indian pharmaceutical organizations Cipla Ltd, Jubilant Sciences Ltd and secretly held Hetero Labs Ltd in

    Hetero, Cipla get gesture to make, market antiviral medication remdesivir

    India’s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for “confined crisis use” on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed

    Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg

    Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only

    Cipla dispatches nonexclusive rendition of remdesivir in India

    Pharma important Cipla on Wednesday said it has launched its own generic version of antiviral drug remdesivir at a cost which is one of the lowest internationally and is seeking to supply over 80,000 vials over the first month. The company, however, did not disclose the purchase price of the medicine. Cipla had earlier said

    Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath

    Drug firm Jubilant Life Sciences on Saturday said it has introduced 1,000 vials of antiviral drug Remdesivir that it sells under the brand name’JUBI-R’ into Uttar Pradesh Chief Minister Yogi Adityanath. The drug has been made accessible to over 1,000 hospitals supplying COVID-19 treatment in India throughout the organization’s distribution system, Jubilant Life Sciences said

    Cipla scales up assembling of remdesivir to fulfill high need

    Medicine manufacturer Cipla said on Tuesday it is rising up the production of antiviral drug remdesivir, used in COVID-19 treatment, by manufacturing the drug at its Goa plant. “Presently the requirement is enormous for remdesivir, also we’re scaling up our internal production of Remdesivir,” Kedar Upadhye, global chief financial officer of Cipla, told Moneycontrol. Upadhye

    WHO-drove COVID-19 medication plot copies down on antibodies, steroids and disregards remdesivir

    A World Health Organization-led scheme to provide COVID-19 drugs to poor countries is gambling on experimental monoclonal antibody treatments and steroids but is shunning Gilead’s remdesivir blockbuster therapy, an internal document shows. The WHO draft document, seen by Reuters and dated October 30, states the priorities are to secure monoclonal antibodies in a tight market